ERLIG

Natalie Tatum, a PDRA in the structural biology group, presented the DDU’s work on Fraglites at ELRIG Drug Discovery Digital 2020. FragLites are small, halogenated fragment compounds specifically designed for X-ray crystallographic screening of potential drug targets. Originally validated on the cyclin-dependent kinase CDK2, we highlighted their ability to differentiate druggabilities within a specific target class. Further, through comparison to deposited structural data and computational druggability assessments, we showed FragLites to bind novel and unique positions which are under-predicted by commonly deployed methods. With relatively high hit-rates, FragLites are therefore an excellent pre-screening tool to provide target ligandability assessment as well as hit matter for development. Publications on the new targets, computational study and our PepLite platform respectively are forthcoming.

Last modified: Sat, 17 Oct 2020 08:25:52 BST